Form 8-K - Current report:
SEC Accession No. 0000950170-24-133693
Filing Date
2024-12-05
Accepted
2024-12-05 16:17:12
Documents
12
Period of Report
2024-12-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kalv-20241205.htm   iXBRL 8-K 43278
2 EX-99.1 kalv-ex99_1.htm EX-99.1 179954
  Complete submission text file 0000950170-24-133693.txt   348081

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kalv-20241205.xsd EX-101.SCH 24862
14 EXTRACTED XBRL INSTANCE DOCUMENT kalv-20241205_htm.xml XML 4718
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 241529321
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)